SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

Andere Sprachen Shin Nippon Biomedical Laboratories, Ltd. OTC Markets

Aktien

A0BMJN

JP3379950003

SBLOF

Markt geschlossen - OTC Markets Andere Börsenplätze 17:58:04 16.05.2023			% 5 Tage	% 1. Jan.
16,97 ^USD	-.--%		-.--%	-.--%

08.05.	Shin Nippon Biomedical Laboratories, Ltd. kündigt für das am 31. März 2024 endende Geschäftsjahr eine Dividende an, zahlbar am 25. Juni 2024; gibt eine Prognose für das zweite Quartal und das Ende des Geschäftsjahres 2025 ab	CI
08.05.	Shin Nippon Biomedical Laboratories, Ltd. stellt konsolidierte Gewinnprognosen für die sechs Monate bis zum 30. September 2024 und das Jahr bis zum 31. März 2025 vor	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025	08.05.
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025	08.05.
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	02.02.
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval	18.01.
Shin Nippon Biomedical Laboratories : 英語版株主通信（2023/04/01~2023/09/30）を発行しました	27.12.
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024	07.11.
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	02.08.23
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	02.08.23
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be presented at the American Headache Society's 65th Annual Scientific Meeting	16.06.23
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting	15.06.23
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting	15.06.23
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	08.06.23
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	08.05.23
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	08.05.23
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023	08.05.23
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	08.05.23
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	18.04.23
Sector Update: Health Care Stocks Higher Premarket Monday	17.04.23
Bank Earnings in Focus as US Equity Futures Tread Water	17.04.23
Top Premarket Gainers	17.04.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Shin Nippon Biomedical Laboratories, Ltd. OTC Markets

Aktien

A0BMJN

JP3379950003

SBLOF

Andere Sprachen

Filter